Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
暂无分享,去创建一个
[1] A. Allen,et al. Challenges and opportunities in NASH drug development , 2023, Nature Medicine.
[2] Wen-Ying Yu,et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications , 2022, Frontiers in Cellular and Infection Microbiology.
[3] Quan Luo,et al. α-D-1,3-glucan from Radix Puerariae thomsonii improves NAFLD by regulating the intestinal flora and metabolites. , 2022, Carbohydrate polymers.
[4] H. Tilg,et al. Gut-liver axis: Pathophysiological concepts and clinical implications. , 2022, Cell metabolism.
[5] Y. Zou,et al. Polysaccharide from Salviae miltiorrhizae Radix et Rhizoma Attenuates the Progress of Obesity-Induced Non-Alcoholic Fatty Liver Disease through Modulating Intestinal Microbiota-Related Gut–Liver Axis , 2022, International journal of molecular sciences.
[6] Chenyang Zhao,et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) , 2022, Signal Transduction and Targeted Therapy.
[7] Jian-ping Luo,et al. Bioactive polysaccharides and their potential health benefits in reducing the risks of atherosclerosis: A review. , 2022, Journal of food biochemistry.
[8] Z. Deng,et al. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial , 2022, Frontiers in Cellular and Infection Microbiology.
[9] Guoquan Xu,et al. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats. , 2022, Food & function.
[10] K. Clément,et al. Risk assessment with gut microbiome and metabolite markers in NAFLD development , 2022, Science Translational Medicine.
[11] Junping Zheng,et al. Structural characterization of Poria cocos oligosaccharides and their effects on the hepatic metabolome in high-fat diet-fed mice. , 2022, Food & function.
[12] M. Zheng,et al. Non-alcoholic Fatty Liver Disease: Current Global Burden. , 2022, Seminars in liver disease.
[13] Hongtao Liu,et al. Structural characterization and preventive effect on non-alcoholic fatty liver disease of oligosaccharides from Bletilla striata. , 2022, Food & function.
[14] S. Withers,et al. Carbohydrate-active enzymes (CAZymes) in the gut microbiome , 2022, Nature Reviews Microbiology.
[15] Shaoqi Yang,et al. Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice. , 2022, Biochemical and biophysical research communications.
[16] G. Ma,et al. Mechanisms and Active Compounds Polysaccharides and Bibenzyls of Medicinal Dendrobiums for Diabetes Management , 2022, Frontiers in Nutrition.
[17] Xubin Huang,et al. Lentinan Supplementation Protects the Gut–Liver Axis and Prevents Steatohepatitis: The Role of Gut Microbiota Involved , 2022, Frontiers in Nutrition.
[18] J. Duan,et al. A homogeneous polysaccharide from Lycium barbarum: Structural characterizations, anti-obesity effects and impacts on gut microbiota. , 2021, International journal of biological macromolecules.
[19] M. Nguyen,et al. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[20] Lu-Lu Gao,et al. Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation. , 2021, International journal of biological macromolecules.
[21] Youlin Zhang,et al. Walnut green husk polysaccharides prevent obesity, chronic inflammatory responses, nonalcoholic fatty liver disease and colonic tissue damage in high-fat diet fed rats. , 2021, International journal of biological macromolecules.
[22] M. Xie,et al. Polysaccharides from fermented Momordica charantia L. with Lactobacillus plantarum NCU116 ameliorate metabolic disorders and gut microbiota change in obese rats. , 2021, Food & function.
[23] W. Jia,et al. Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice , 2021, Gut microbes.
[24] L. Canesi,et al. Brown-Algae Polysaccharides as Active Constituents against Nonalcoholic Fatty Liver Disease , 2020, Planta Medica.
[25] H. Ouyang,et al. PL-S2, a homogeneous polysaccharide from Radix Puerariae lobatae, attenuates hyperlipidemia via farnesoid X receptor (FXR) pathway-modulated bile acid metabolism. , 2020, International journal of biological macromolecules.
[26] Bangmao Wang,et al. Microbial Metabolites: Critical Regulators in NAFLD , 2020, Frontiers in Microbiology.
[27] M. Puig-Domingo,et al. Microbiota, Fiber, and NAFLD: Is There Any Connection? , 2020, Nutrients.
[28] Hualiang Huang,et al. Extraction, separation, modification, structural characterization, and antioxidant activity of plant polysaccharides , 2020, Chemical biology & drug design.
[29] C. Aguilar-Salinas,et al. Trimethylamine N-Oxide levels are associated with NASH in obese subjects with type 2 diabetes. , 2020, Diabetes & metabolism.
[30] B. Schnabl,et al. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. , 2020, Cell host & microbe.
[31] Yichen Hu,et al. Dietary quinoa (Chenopodium quinoa Willd.) polysaccharides ameliorate high-fat diet-induced hyperlipidemia and modulate gut microbiota. , 2020, International journal of biological macromolecules.
[32] Youlin Zhang,et al. The protective effects of walnut green husk polysaccharide on liver injury, vascular endothelial dysfunction and disorder of gut microbiota in high fructose-induced mice. , 2020, International journal of biological macromolecules.
[33] Jiaofeng Huang,et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[34] Yun Niu,et al. Effects of Nigella sativa seed polysaccharides on type 2 diabetic mice and gut microbiota. , 2020, International journal of biological macromolecules.
[35] V. Wong,et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.
[36] R. Jalan,et al. Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease , 2020, Hepatology.
[37] A. Sanyal,et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.
[38] K. Clément,et al. Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? , 2020, Gastroenterology.
[39] J. Chiang,et al. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. , 2020, American journal of physiology. Gastrointestinal and liver physiology.
[40] Qianchun Deng,et al. Beneficial effects of flaxseed polysaccharides on metabolic syndrome via gut microbiota in high-fat diet fed mice. , 2020, Food research international.
[41] A. Ichimura,et al. Free Fatty Acid Receptors in Health and Disease. , 2020, Physiological reviews.
[42] A. Xu,et al. Combination of Probiotics and Salvia miltiorrhiza Polysaccharide Alleviates Hepatic Steatosis via Gut Microbiota Modulation and Insulin Resistance Improvement in High Fat-Induced NAFLD Mice , 2019, Diabetes & metabolism journal.
[43] B. Liu,et al. The Positive Effects of Grifola frondosa Heteropolysaccharide on NAFLD and Regulation of the Gut Microbiota , 2019, International journal of molecular sciences.
[44] Yi Feng,et al. MDG-1, an Ophiopogon polysaccharide, restrains process of non-alcoholic fatty liver disease via modulating the gut-liver axis. , 2019, International journal of biological macromolecules.
[45] Jinli Huang,et al. Fucoidan and galactooligosaccharides ameliorate high-fat diet-induced dyslipidemia in rats by modulating the gut microbiota and bile acid metabolism. , 2019, Nutrition.
[46] J. Venter,et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. , 2019, Cell metabolism.
[47] Q. Mei,et al. Modified apple polysaccharide regulates microbial dysbiosis to suppress high-fat diet-induced obesity in C57BL/6J mice , 2019, European Journal of Nutrition.
[48] Mingwei Zhang,et al. A sulfated polysaccharide from Gracilaria Lemaneiformis regulates cholesterol and bile acid metabolism in high-fat diet mice. , 2019, Food & function.
[49] Yan-Yan Zhang,et al. Grifola frondosa polysaccharides ameliorate lipid metabolic disorders and gut microbiota dysbiosis in high-fat diet fed rats. , 2019, Food & function.
[50] M. McCarthy,et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases , 2019, Nature Genetics.
[51] K. Venema,et al. Gut microbial metabolites in obesity, NAFLD and T2DM , 2019, Nature Reviews Endocrinology.
[52] Jie-lun Hu,et al. Dietary compounds and traditional Chinese medicine ameliorate type 2 diabetes by modulating gut microbiota , 2018, Critical reviews in food science and nutrition.
[53] J. González‐Gallego,et al. Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease , 2018, Front. Physiol..
[54] Luyong Zhang,et al. Bile acid regulation: A novel therapeutic strategy in non‐alcoholic fatty liver disease , 2018, Pharmacology & therapeutics.
[55] Baoxue Yang,et al. Ganoderma Lucidum Polysaccharide Peptide Alleviates Hepatoteatosis via Modulating Bile Acid Metabolism Dependent on FXR-SHP/FGF , 2018, Cellular Physiology and Biochemistry.
[56] N. Mousa,et al. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot , 2018, European journal of gastroenterology & hepatology.
[57] Antonio Felix Conde-Martin,et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. , 2018, Gastroenterology.
[58] Hong Chen,et al. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model” , 2018, World journal of gastroenterology.
[59] D. Ojcius,et al. Gut commensal Parabacteroides goldsteinii plays a predominant role in the anti-obesity effects of polysaccharides isolated from Hirsutella sinensis , 2018, Gut.
[60] P. Gentileschi,et al. Molecular Phenomics and Metagenomics of Hepatic Steatosis in Non-Diabetic Obese Women , 2018, Nature Medicine.
[61] Wei Jia,et al. Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis , 2018, Nature Reviews Gastroenterology & Hepatology.
[62] R. Mantegazza,et al. Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis? , 2018, Annals of the New York Academy of Sciences.
[63] Hua Yue,et al. Macrophage responses to the physical burden of cell-sized particles. , 2018, Journal of materials chemistry. B.
[64] N. Petronella,et al. Impact of β2-1 fructan on faecal community change: results from a placebo-controlled, randomised, double-blinded, cross-over study in healthy adults , 2017, British Journal of Nutrition.
[65] I. Bergheim,et al. Short-Term Intake of a Fructose-, Fat- and Cholesterol-Rich Diet Causes Hepatic Steatosis in Mice: Effect of Antibiotic Treatment , 2017, Nutrients.
[66] Jian-Gao Fan,et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. , 2017, Hepatobiliary & pancreatic diseases international : HBPD INT.
[67] Ruixin Zhu,et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD , 2017, Gut.
[68] B. Staels,et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and NAFLD. , 2017 .
[69] Z. Tian,et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production. , 2017, Journal of hepatology.
[70] Q. Pan,et al. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. , 2017, World journal of gastroenterology.
[71] M. Anitha,et al. An Intestinal Farnesoid X Receptor–Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice , 2016, Diabetes.
[72] D. Xia,et al. Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. , 2016, Immunity.
[73] Dustin E. Schones,et al. Vertical sleeve gastrectomy activates GPBAR‐1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice , 2016, Hepatology.
[74] Lei Shi. Bioactivities, isolation and purification methods of polysaccharides from natural products: A review , 2016, International Journal of Biological Macromolecules.
[75] J. Heeren,et al. FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues. , 2016, Cell metabolism.
[76] Lawrence A. David,et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota , 2016, Hepatology.
[77] C. Huttenhower,et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis , 2016, Nature Communications.
[78] S. Mazmanian,et al. Gut biogeography of the bacterial microbiota , 2015, Nature Reviews Microbiology.
[79] M. Gorzelak,et al. Methods for Improving Human Gut Microbiome Data by Reducing Variability through Sample Processing and Storage of Stool , 2015, PloS one.
[80] Y. Chawla,et al. Small intestinal bacterial overgrowth and toll‐like receptor signaling in patients with non‐alcoholic fatty liver disease , 2015, Journal of gastroenterology and hepatology.
[81] Feng Zhang,et al. Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis. , 2012, Cellular signalling.
[82] J. Pessin,et al. Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K ATP channels , 2012 .
[83] A. M. Habib,et al. Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2 , 2012, Diabetes.
[84] B. M. Forman,et al. The G‐Protein‐coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light‐chain enhancer of activated B cells (NF‐κB) in mice , 2011, Hepatology.
[85] G. Musso,et al. Obesity, Diabetes, and Gut Microbiota , 2010, Diabetes Care.
[86] W. Cefalu,et al. Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice , 2009, Diabetes.
[87] S. Strom,et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α‐hydroxylase gene expression , 2009, Hepatology.
[88] Masashi Yanagisawa,et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41 , 2008, Proceedings of the National Academy of Sciences.
[89] D. Häussinger,et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. , 2008, Biochemical and biophysical research communications.
[90] Timothy M Willson,et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[91] F. Gonzalez,et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. , 2003, Gastroenterology.
[92] Masahiro Tohkin,et al. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.
[93] L. Henry,et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.